Incidence, predictors and outcome of drug-eluting stent thrombosis in real-world practice

Journal of Invasive Cardiology

Volumn 22, Issue 10, 2010, Pages 461-464

  Blich, Miry ^a   Zeidan Shwiri, Tawfiq ^a   Petcherski, Sirouch ^a   Osherov, Azriel ^a   Hammerman, Haim ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN; THIENOPYRIDINE DERIVATIVE; ZOTAROLIMUS;

ADULT; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CARDIAC PATIENT; DEATH; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PREDICTOR VARIABLE; PROSPECTIVE STUDY; RISK FACTOR; STENT THROMBOSIS;

ANGIOPLASTY, BALLOON, CORONARY; CLOPIDOL; CORONARY ANGIOGRAPHY; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RISK FACTORS;

EID: 77958198213     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Morice MC, Serruys P W, Sousa JE, et al. A randomized comparison of sirolimus-eluting stent with a standard stent of coronary revascularization. N Engl J Med 2002;346:1773-1780.
2. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents vs. standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
3. Stone G, Ellis S, Cox D, Hermiller J, et al. A polymer based paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
4. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow and moderate release polymer based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-794.
5. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. What is the risk of stent thrombosis associated with the use of paclitaxel eluting stent for percutaneous coronary intervention? A meta-analysis. J Am Coll Cardiol 2005;45:941-946.
6. Moreno R, Fernandez C, Hernandez R, et al. Drug-eluting stent thrombosis: Results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005;45:954-959.
7. Indolfi C, Pavia M, Angelillo I F. Drug-eluting stents versus bare-metal stents in percutaneous coronary interventions. Am J Cardiol 2005;95:1146-1152.
8. Pandhi P, Shafiq N, Malhotra S. Drug-eluting stents do not increase the risk of stent thrombosis, but longer stents may be associated with greater incidence of thrombosis. Evid Based Cardiovasc Med 2005;9:184-186.
9. Van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis. The Dutch stent thrombosis registry. J Am Coll Cardiol 2009;53:1399-1409.
10. Listro F, Colombo A. Late acute thrombosis after paclitaxel-eluting stent implantation. Heart 2001;86:262-264.
11. Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off label use of drug-eluting stent. JAMA 2007;2001-2009.
12. McFadden E P, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-1521.
13. Waters RE, Kandzari DE, Phillips HR, et al. Late thrombosis following treatment of in stent restenosis with drug eluting stents after discontinuation of antiplatelet therapy. Catheter Cardiovasc Interv 2005;65:520-524.
14. Stabile E, Cheneau E, Kinnaird T, et al. Late thrombosis in cipher stents after the discontinuation of antiplatelet therapy. Cardiovasc Radiat Med 2004;5:173-176.
15. Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004;109:1930-1932.
16. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence predictors and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130.
17. Ong AT, McFadden E P, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug eluting stents. J Am Coll Cardiol 2005;45:2088-2092.
18. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: A pooled analysis of multicenter coronary stent clinical trials. Circulation 2002;106:1949-1956.
19. Rodriguez AE, Mieres J, Fernandez Pereira C, et al. Coronary stent thrombosis in the current drug eluting stent era: Insights from ERACI 3 trial. J Am Coll Cardiol 2006;47:205-207.
20. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two institutional cohort study. Lancet 2007;369:667-678.
21. Wenaweser P, Daemen J, Zwahlen M, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. J Am Coll Cardiol 2008;52:1134-1140.
22. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-1029.
23. Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimuseluting stents with bare-metal stents. N Engl J Med 2007;356:989-997.
24. Planer D, Beyar R, Almagor Y, et al. Long term outcome and predictors of clinical events after insertion of sirolimus-eluting stent in one or more native coronary arteries (from the Israeli arm of the e-Cypher registry). Am J Cardiol 2008;101:953-959.
25. Eisenstein EL, Anstrom KJ, Kong D F, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-168.
26. Chhatriwalla AK, Bhatt DL. Should dual antiplatelet therapy after drug-eluting stent be continued for more than 1 year? Dual antiplatelet therapy after drug-eluting stent should be continued for more than 1 year and preferably indefinitely. Circ Cardiovasc Intervent 2008;1:217-225.
27. Patti G, Nusca A, Mangiacapra F, et al. Point of care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDAPRO study. J Am Coll Cardiol 2008;52:1128-1133.
28. Virmani R, Farb A, Guagliumi G, Kolodgie FD. Drug-eluting stents: Caution and concerns for long term outcome. Coron Artery Dis 2004;15:313-318.
29. Olivier AC, Hollman JL. Late in stent thrombosis in a patient with systemic lupus erythematosus and hyperhomocysteinemia while on clopidogrel and aspirin. J Invasive Cardiol 2006;18: E185-E187.
30. Acar G, Dogan A, Altinbas A, Turker Y. Recurrent acute stent thrombosis associated with protein C and S deficiencies. Int J Cardiovasc Imaging 2006;22:333-337.
31. Santos JL, Cruz I, Herrero FM, et al. Recurrent coronary thrombosis, gactor 5 leiden, primary antiphospholipid syndrome and HIV. Rev Esp Cardiol 2004;57:997-999.